X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Reblozyl (luspatercept-aamt) first-in-class therapeutic option, promotes late-stage red blood cell maturation in animal models, is currently approved in the U.S. for treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.
Lead Product(s): Luspatercept
Therapeutic Area: Genetic Disease Product Name: Reblozyl
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
Through the successful completion of the acquisition of Acceleron Pharma, Merck would be growing its cardiovascular portfolio and pipeline, including Acceleron’s lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACE-011
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck
Deal Size: $11,500.0 million Upfront Cash: $11,500.0 million
Deal Type: Acquisition November 19, 2021
Details:
Under the terms of the acquisition agreement, Merck will acquire all outstanding shares of Acceleron including its pipeline having lead therapeutic candidate, sotatercept, in Phase 3 trials as add-on to current standard of care for the treatment of PAH.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACE-011
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $11,500.0 million Upfront Cash: $11,500.0 million
Deal Type: Acquisition September 30, 2021
Details:
Results showed treatment with Reblozyl plus best supportive care improved anemia in 77% of patients compared to placebo. Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval.
Lead Product(s): Luspatercept
Therapeutic Area: Genetic Disease Product Name: Reblozyl
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
The SPECTRA Phase 2 trial is a single arm, open-label, multi-center exploratory study to determine the eects of sotatercept plus standard of care in adults with WHO functional class III PAH.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACE-011
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2021
Details:
A total of 106 patients were randomized in a 3:3:4 ratio to receive placebo, sotatercept 0.3 mg/kg, or sotatercept 0.7 mg/kg subcutaneously every three weeks on top of standard-of-care therapies.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACE-011
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2021
Details:
The PULSAR Phase 2 trial evaluating sotatercept in combination with approved PAH-specific medicines in patients with PAH achieved its primary endpoint of improvement in pulmonary vascular resistance and its key secondary endpoint of improvement in 6-minute walk distance.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACE-011
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2021
Details:
Results show patients treated with sotatercept experienced improvements in hemodynamic and functional endpoints compared with placebo.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACE-011
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2021
Details:
Acceleron is currently advancing a Phase 3 development plan for sotatercept, beginning with the registrational trial known as STELLAR expected to initiate by the end of this year.
Lead Product(s): Sotatercept
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ACE-011
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Acceleron plans to initiate Phase 1b/Phase 2 trial in patients with systemic sclerosis-associated interstitial lung disease in 2021.
Lead Product(s): ACE-1334
Therapeutic Area: Immunology Product Name: ACE-1334
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
